ClinicalTrials.gg
CompletedNCT00676403Updated Feb 10, 2021Results posted

Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

A Phase 2 interventional study of placebo and Pregabalin in Restless Legs Syndrome, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 25 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-10.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.

Enrollment
26th of 95
137 · median 46
Started
2008
with 5 others
Phase 2
16 of 107
1 open now
Registered
30th of 107
by date
Lead sponsor
3 of 107
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 26th largest by enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2008, is one of 16 in phase 2, and was the 30th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Restless Legs Syndrome with a site in United States, or all of them as a file.
02

Study summary

To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients

03

Conditions studied

  • Restless Legs Syndrome

Keywords

  • pregabalin, RLS, efficacy, safety
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe idiopathic RLS
  • symptoms occur predominantly in the evening
  • symptoms interfere with sleep onset or maintenance

Exclusion criteria

Exclusion Criteria:

  • Any secondary RLS
  • require treatment for daytime RLS symptoms
  • symptomatic neuropathies
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
137 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: placebo

  • Experimental
    2

    investigational treatment

    Drug: Pregabalin

  • Experimental
    3

    investigational treatment

    Drug: Pregabalin

  • Experimental
    4

    investigational treatment

    Drug: Pregabalin

  • Experimental
    5

    investigational treatment

    Drug: Pregabalin

  • Experimental
    6

    investigational treatment

    Drug: Pregabalin

Interventions

  • Drugplacebo

    Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks

    Also known as: Sugar pill

  • 50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

    Also known as: Lyrica, PD 0144723; CI-1008

  • 100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

    Also known as: Lyrica, PD 0144723; CI-1008

  • 150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

    Also known as: Lyrica, PD 0144723; CI-1008

  • 300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

    Also known as: Lyrica, PD 0144723; CI-1008

  • 450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

    Also known as: Lyrica, PD 0144723; CI-1008

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6

    IRLS: Subject-rated instrument to assess RLS symptom severity and impact on daily living; 10 items yielding 2 subscale scores and 1 global (total) score. Subscale scores: symptom severity (6 items) and impact on daily living (3 items), with item 5 (daytime somnolence due to RLS) loaded equally on both subscales. Global score: calculated from all 10 items. Subscale score ranges: symptom severity 0-24, impact of daily living 0-12; global score range: 0-40. Lower scores reflect lower severity and better quality of life. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Number of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)

    Clinical Global Impression - Improvement Scale (CGI-I): 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Number of subjects responding to treatment at Week 6 with respect to dose level. CGI-I Responders = subjects who reported CGI-I scores of very much improved or much improved.

    Time frame: Week 6

  2. Number of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)

    CGI-S Scale: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Last Observation Carried Forward (LOCF)

  3. Subjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline

    Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Latency subscale (time to fall asleep \[in minutes\]): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Lower score reflects greater ease (shorter time) in falling asleep. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6

  4. Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline

    Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Hours of sleep subscale reflects change in hours of sleep from baseline. Numerical rating completed by the subject 30 minutes after waking; recall period is the night before.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6

  5. Subjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline

    Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Number of awakenings subscale: numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Fewer awakenings reflect better quality of sleep. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6

  6. Subjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline

    Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Total wake time after sleep onset subscale (in minutes): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Reduction = improvement. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6

  7. Subjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline

    Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Quality of sleep subscale: visual analog scale ranging from 1 (very poor) to 100 (excellent) completed by the subject 30 minutes after waking; recall period is the night before. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6

  8. Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep quantity and quality over the past week; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Disturbance Subscale score (4 items): range 0-100; lower score indicates less disturbance. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6

  9. Medical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality over the past week. Comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Snoring Subscale score (1 item): range 0-100, lower score indicates less snoring. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6

  10. Medical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week ; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Awaken Short of Breath or with Headache subscale score range: 0-100; lower score indicates less difficulty. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6

  11. Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Adequacy Subscale score range: 0-100; higher scores indicates greater sleep adequacy. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6

  12. Medical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Somnolence Subscale score range: 0-100; higher score indicates less somnolence. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline,, Week 1, Week 2, Week 4, Week 6

  13. Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Quantity (1 item) subscale score range: 0-24 hours. Change from Baseline in number of hours slept. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline,, Week 1, Week 2, Week 4, Week 6

  14. Medical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Problems Index I (6 items): composite index score range 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6

  15. Medical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Composite index scores are sleep problems Index I (6 items) and sleep problems Index II (9 items). 9-Item Sleep Problems Index range: 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6

  16. Medical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week

    MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Optimal Sleep subscale is derived from sleep quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours of sleep per night.

    Time frame: Week 1, Week 2, Week 4, Week 6

  17. Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6

    RLS QoL: subject-rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life. Recall period is the month prior to the assessment. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 6

  18. Medical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Recall period: month prior to the assessment. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Week 6

  19. Medical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Self-evaluated change in health status: 5 Likert-type response categories ranging from "much worse now" to much better now." Recall period: month prior to the assessment.

    Time frame: Baseline, Week 6

07

Results

Posted Feb 4, 2010

Participant flow

Participant flow — Overall Study
MilestonePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Started232223222423
Completed212022172318
Not completed221515
Withdrew: Adverse event120512
Withdrew: Lost to follow-up000001
Withdrew: Reason unspecified101001
Withdrew: Withdrawal by subject000001

Outcome measures

PrimaryChange From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6

IRLS: Subject-rated instrument to assess RLS symptom severity and impact on daily living; 10 items yielding 2 subscale scores and 1 global (total) score. Subscale scores: symptom severity (6 items) and impact on daily living (3 items), with item 5 (daytime somnolence due to RLS) loaded equally on both subscales. Global score: calculated from all 10 items. Subscale score ranges: symptom severity 0-24, impact of daily living 0-12; global score range: 0-40. Lower scores reflect lower severity and better quality of life. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · scores on scale
Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6-7.73 ± 1.720-11.83 ± 1.771-11.76 ± 1.694-16.02 ± 1.865-12.89 ± 1.713-16.26 ± 1.771
Statistical analysis
  • Placebo vs Pregabalin 50 mg vs Pregabalin 100 mg vs Pregabalin 150 mg vs Pregabalin 300 mg vs Pregabalin 450 mg · ED-50: Bootstrap Method · Median difference (final values): 37.3 · 95% CI 0.1 to 157.7Non-convergence for the non-liner model occurred in some bootstrap samples which were not included in summarizing the ED50 distribution or confidence interval.
  • Placebo vs Pregabalin 50 mg vs Pregabalin 100 mg vs Pregabalin 150 mg vs Pregabalin 300 mg vs Pregabalin 450 mg · ED 90: Bootstrap Method · Median difference (final values): 123.9 · 95% CI 0.4 to 523.9Non-convergence for the non-liner model occurred in some bootstrap samples which were not included in summarizing the ED90 distribution or confidence interval.
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0983 · Mean difference (final values): -4.10 · 95% CI -8.97 to 0.77
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.0966 · Mean difference (final values): -4.03 · 95% CI -8.78 to 0.73
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0013 · Mean difference (final values): -8.29 · 95% CI -13.31 to -3.28
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.0353 · Mean difference (final values): -5.16 · 95% CI -9.96 to -0.36
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0006 · Mean difference (final values): -8.53 · 95% CI -13.40 to -3.67
SecondaryNumber of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)

Clinical Global Impression - Improvement Scale (CGI-I): 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Number of subjects responding to treatment at Week 6 with respect to dose level. CGI-I Responders = subjects who reported CGI-I scores of very much improved or much improved.

Time frame:
Week 6
Reported as:
Number · participants
Number of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)
participantsPlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 6: Responders (n=21, 20, 22, 18, 23, 20)131215111718
Week 6: Non-Responders887762
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Cochran-Mantel-Haenszel · p = 0.8784
  • Placebo vs Pregabalin 100 mg · Cochran-Mantel-Haenszel · p = 0.6767
  • Placebo vs Pregabalin 150 mg · Cochran-Mantel-Haenszel · p = 0.8955
  • Placebo vs Pregabalin 300 mg · Cochran-Mantel-Haenszel · p = 0.9505
  • Placebo vs Pregabalin 450 mg · Cochran-Mantel-Haenszel · p = 0.0466
SecondaryNumber of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)

CGI-S Scale: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6, Last Observation Carried Forward (LOCF)
Reported as:
Number · participants
Number of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)
participantsPlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Baseline: Normal, Not at All Ill000000
Baseline: Borderline, Mentally Ill000000
Baseline: Mildly Ill112422
Baseline: Moderately Ill6985116
Baseline: Markedly Ill787535
Baseline: Severely Ill8367810
Baseline: Among the Most Extremely Ill110100
Week 1: Normal, Not at All Ill111103
Week 1: Borderline, Mentally Ill011142
Week 1: Mildly Ill465857
Week 1: Moderately Ill1085768
Week 1: Markedly Ill435132
Week 1: Severely Ill423251
Week 1: Among the Most Extremely Ill000000
Week 2: Normal, Not at All Ill021237
Week 2: Borderline, Mentally Ill342362
Week 2: Mildly Ill1059748
Week 2: Moderately Ill355653
Week 2: Markedly Ill334030
Week 2: Severely Ill311110
Week 2: Among the Most Extremely Ill100000
Week 4: Normal, Not at All Ill122548
Week 4: Borderline, Mentally Ill422265
Week 4: Mildly Ill8711544
Week 4: Moderately Ill466552
Week 4: Markedly Ill321121
Week 4: Severely Ill221120
Week 4: Among the Most Extremely Ill000000
Week 6: Normal, Not at All Ill134467
Week 6: Borderline, Mentally Ill334445
Week 6: Mildly Ill1167776
Week 6: Moderately Ill255311
Week 6: Markedly Ill222041
Week 6: Severely Ill210010
Week 6: Among the Most Extremely Ill000000
LOCF: Normal134467
LOCF: Borderline, Mentally Ill334446
LOCF: Mildly Ill1267977
LOCF: Moderately Ill265511
LOCF: Markedly Ill222041
LOCF: Severely Ill221021
LOCF: Among the Most Extremely Ill100000
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Cochran-Mantel-Haenszel · p = 0.3876
  • Placebo vs Pregabalin 100 mg · Cochran-Mantel-Haenszel · p = 0.7959
  • Placebo vs Pregabalin 150 mg · Cochran-Mantel-Haenszel · p = 0.2032
  • Placebo vs Pregabalin 300 mg · Cochran-Mantel-Haenszel · p = 0.7032
  • Placebo vs Pregabalin 450 mg · Cochran-Mantel-Haenszel · p = 0.0551
  • Placebo vs Pregabalin 50 mg · Cochran-Mantel-Haenszel · p = 0.4100
  • Placebo vs Pregabalin 100 mg · Cochran-Mantel-Haenszel · p = 0.6524
  • Placebo vs Pregabalin 150 mg · Cochran-Mantel-Haenszel · p = 0.3219
  • Placebo vs Pregabalin 300 mg · Cochran-Mantel-Haenszel · p = 0.3509
  • Placebo vs Pregabalin 450 mg · Cochran-Mantel-Haenszel · p = 0.0053
  • Placebo vs Pregabalin 50 mg · Cochran-Mantel-Haenszel · p = 0.9835
  • Placebo vs Pregabalin 100 mg · Cochran-Mantel-Haenszel · p = 0.6668
  • Placebo vs Pregabalin 150 mg · Cochran-Mantel-Haenszel · p = 0.2823
  • Placebo vs Pregabalin 300 mg · Cochran-Mantel-Haenszel · p = 0.5687
  • Placebo vs Pregabalin 450 mg · Cochran-Mantel-Haenszel · p = 0.0043
  • Placebo vs Pregabalin 50 mg · Cochran-Mantel-Haenszel · p = 0.8662
  • Placebo vs Pregabalin 100 mg · Cochran-Mantel-Haenszel · p = 0.3656
  • Placebo vs Pregabalin 150 mg · Cochran-Mantel-Haenszel · p = 0.0806
  • Placebo vs Pregabalin 300 mg · Cochran-Mantel-Haenszel · p = 0.5381
  • Placebo vs Pregabalin 450 mg · Cochran-Mantel-Haenszel · p = 0.0090
  • Placebo vs Pregabalin 50 mg · Cochran-Mantel-Haenszel · p = 0.9748
  • Placebo vs Pregabalin 100 mg · Cochran-Mantel-Haenszel · p = 0.3936
  • Placebo vs Pregabalin 150 mg · Cochran-Mantel-Haenszel · p = 0.1563
  • Placebo vs Pregabalin 300 mg · Cochran-Mantel-Haenszel · p = 0.6357
  • Placebo vs Pregabalin 450 mg · Cochran-Mantel-Haenszel · p = 0.0133
SecondarySubjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline

Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Latency subscale (time to fall asleep \[in minutes\]): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Lower score reflects greater ease (shorter time) in falling asleep. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Reported as:
Least squares mean · minutes
Subjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline
minutesPlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 1-9.8 ± 5.60-16.3 ± 5.76-13.2 ± 5.60-10.4 ± 5.76-9.1 ± 5.65-20.2 ± 5.62
Week 2-8.9 ± 5.60-20.7 ± 5.84-17.2 ± 5.65-16.3 ± 6.00-13.0 ± 5.71-34.3 ± 5.69
Week 3-14.6 ± 5.71-18.9 ± 5.90-13.1 ± 5.60-17.8 ± 6.00-17.8 ± 5.71-33.7 ± 5.88
Week 4-13.6 ± 5.66-20.4 ± 5.90-20.4 ± 5.60-18.2 ± 6.00-18.2 ± 5.71-37.1 ± 5.82
Week 5-15.9 ± 5.71-26.8 ± 5.90-17.6 ± 5.60-24.0 ± 6.07-13.4 ± 5.71-36.1 ± 5.82
Week 6-12.4 ± 5.71-25.4 ± 5.90-19.5 ± 5.65-25.1 ± 6.14-10.1 ± 5.71-34.9 ± 5.82
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.4133 · Mean difference (final values): -6.6 · 95% CI -22.4 to 9.3
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.6676 · Mean difference (final values): -3.4 · 95% CI -19.0 to 12.2
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.9355 · Mean difference (final values): -0.7 · 95% CI -16.5 to 15.2
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.9355 · Mean difference (final values): 0.6 · 95% CI -15.1 to 16.4
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.1895 · Mean difference (final values): -10.5 · 95% CI -26.1 to 5.2
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1443 · Mean difference (final values): -11.9 · 95% CI -27.8 to 4.1
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.2946 · Mean difference (final values): -8.4 · 95% CI -24.0 to 7.3
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.3686 · Mean difference (final values): -7.4 · 95% CI -23.6 to 8.8
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.6079 · Mean difference (final values): -4.1 · 95% CI -19.9 to 11.7
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0016 · Mean difference (final values): -25.5 · 95% CI -41.2 to -9.7
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.5976 · Mean difference (final values): -4.3 · 95% CI -20.5 to 11.8
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.8527 · Mean difference (final values): 1.5 · 95% CI -14.3 to 17.3
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.6973 · Mean difference (final values): -3.2 · 95% CI -19.6 to 13.1
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.6895 · Mean difference (final values): -3.2 · 95% CI -19.2 to 12.7
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0209 · Mean difference (final values): -19.1 · 95% CI -35.2 to -2.9
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.4084 · Mean difference (final values): -6.8 · 95% CI -22.9 to 9.3
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.3958 · Mean difference (final values): -6.8 · 95% CI -22.5 to 8.9
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.5776 · Mean difference (final values): -4.6 · 95% CI -20.9 to 11.7
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.5665 · Mean difference (final values): -4.6 · 95% CI -20.5 to 11.3
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0041 · Mean difference (final values): -23.5 · 95% CI -39.6 to -7.5
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1842 · Mean difference (final values): -10.9 · 95% CI -27.1 to 5.2
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.8269 · Mean difference (final values): -1.8 · 95% CI -17.5 to 14.0
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.3319 · Mean difference (final values): -8.1 · 95% CI -24.5 to 8.3
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.7552 · Mean difference (final values): 2.5 · 95% CI -13.4 to 18.5
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0137 · Mean difference (final values): -20.3 · 95% CI -36.3 to -4.2
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1157 · Mean difference (final values): -13.0 · 95% CI -29.2 to 3.2
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.3791 · Mean difference (final values): -7.1 · 95% CI -22.9 to 8.7
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.1329 · Mean difference (final values): -12.7 · 95% CI -29.2 to 3.9
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.7723 · Mean difference (final values): 2.3 · 95% CI -13.6 to 18.3
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0063 · Mean difference (final values): -22.5 · 95% CI -38.6 to -6.4
SecondarySubjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline

Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Hours of sleep subscale reflects change in hours of sleep from baseline. Numerical rating completed by the subject 30 minutes after waking; recall period is the night before.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Reported as:
Least squares mean · hours
Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline
hoursPlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 10.23 ± 0.1770.57 ± 0.1830.29 ± 0.1770.55 ± 0.1820.45 ± 0.1770.72 ± 0.178
Week 20.36 ± 0.1770.65 ± 0.1860.52 ± 0.1790.81 ± 0.1920.76 ± 0.1801.07 ± 0.181
Week 30.36 ± 0.1820.61 ± 0.1880.53 ± 0.1770.89 ± 0.1920.72 ± 0.1801.32 ± 0.189
Week 40.27 ± 0.1800.81 ± 0.1880.46 ± 0.1770.93 ± 0.1920.65 ± 0.1801.03 ± 0.187
Week 50.37 ± 0.1821.03 ± 0.1880.43 ± 0.1770.97 ± 0.1950.61 ± 0.1801.43 ± 0.187
Week 60.19 ± 0.1820.84 ± 0.1880.42 ± 0.1790.95 ± 0.1980.44 ± 0.1801.11 ± 0.187
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1715 · Mean difference (final values): 0.35 · 95% CI -0.15 to 0.85
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.7944 · Mean difference (final values): 0.07 · 95% CI -0.43 to 0.56
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.1994 · Mean difference (final values): 0.33 · 95% CI -0.17 to 0.83
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.3652 · Mean difference (final values): 0.23 · 95% CI -0.27 to 0.72
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0481 · Mean difference (final values): 0.50 · 95% CI 0.00 to 0.99
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.2501 · Mean difference (final values): 0.30 · 95% CI -0.21 to 0.80
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.5191 · Mean difference (final values): 0.16 · 95% CI -0.33 to 0.66
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0817 · Mean difference (final values): 0.46 · 95% CI -0.06 to 0.97
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1146 · Mean difference (final values): 0.40 · 95% CI -0.10 to 0.90
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0054 · Mean difference (final values): 0.71 · 95% CI 0.21 to 1.21
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.3389 · Mean difference (final values): 0.25 · 95% CI -0.26 to 0.76
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.5079 · Mean difference (final values): 0.17 · 95% CI -0.33 to 0.67
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0453 · Mean difference (final values): 0.53 · 95% CI 0.01 to 1.05
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1622 · Mean difference (final values): 0.36 · 95% CI -0.15 to 0.86
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0003 · Mean difference (final values): 0.96 · 95% CI 0.45 to 1.48
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0383 · Mean difference (final values): 0.54 · 95% CI 0.03 to 1.05
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.4495 · Mean difference (final values): 0.19 · 95% CI -0.31 to 0.69
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0135 · Mean difference (final values): 0.65 · 95% CI 0.14 to 1.17
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1423 · Mean difference (final values): 0.37 · 95% CI -0.13 to 0.87
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0035 · Mean difference (final values): 0.76 · 95% CI 0.25 to 1.27
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0125 · Mean difference (final values): 0.66 · 95% CI 0.14 to 1.17
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.8021 · Mean difference (final values): 0.06 · 95% CI -0.44 to 0.56
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0249 · Mean difference (final values): 0.60 · 95% CI 0.08 to 1.13
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.3383 · Mean difference (final values): 0.25 · 95% CI -0.26 to 0.75
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): 1.06 · 95% CI 0.55 to 1.57
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0133 · Mean difference (final values): 0.65 · 95% CI 0.14 to 1.17
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.3820 · Mean difference (final values): 0.22 · 95% CI -0.28 to 0.73
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0053 · Mean difference (final values): 0.75 · 95% CI 0.23 to 1.28
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.3258 · Mean difference (final values): 0.25 · 95% CI -0.25 to 0.76
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0005 · Mean difference (final values): 0.92 · 95% CI 0.41 to 1.43
SecondarySubjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline

Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Number of awakenings subscale: numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Fewer awakenings reflect better quality of sleep. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Reported as:
Least squares mean · awakenings
Subjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline
awakeningsPlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 1-0.5 ± 0.21-0.9 ± 0.21-1.0 ± 0.21-1.2 ± 0.21-0.7 ± 0.21-0.8 ± 0.21
Week 2-0.7 ± 0.21-1.0 ± 0.22-1.3 ± 0.21-1.3 ± 0.23-1.3 ± 0.21-1.1 ± 0.21
Week 3-0.7 ± 0.21-1.0 ± 0.22-1.0 ± 0.21-1.3 ± 0.23-1.2 ± 0.21-1.4 ± 0.22
Week 4-0.9 ± 0.21-1.1 ± 0.22-1.2 ± 0.21-1.5 ± 0.23-1.1 ± 0.21-1.2 ± 0.22
Week 5-0.8 ± 0.21-1.3 ± 0.22-1.0 ± 0.21-1.6 ± 0.23-1.2 ± 0.21-1.5 ± 0.22
Week 6-1.0 ± 0.21-1.0 ± 0.22-1.1 ± 0.21-1.5 ± 0.23-1.0 ± 0.21-1.2 ± 0.22
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1429 · Mean difference (final values): -0.4 · 95% CI -1.0 to 0.1
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.0547 · Mean difference (final values): -0.6 · 95% CI -1.2 to 0.0
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0095 · Mean difference (final values): -0.8 · 95% CI -1.4 to -0.2
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.3676 · Mean difference (final values): -0.3 · 95% CI -0.9 to 0.3
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.2959 · Mean difference (final values): -0.3 · 95% CI -0.9 to 0.3
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.3435 · Mean difference (final values): -0.3 · 95% CI -0.9 to 0.3
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.0895 · Mean difference (final values): -0.5 · 95% CI -1.1 to 0.1
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0844 · Mean difference (final values): -0.5 · 95% CI -1.1 to 0.1
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.0675 · Mean difference (final values): -0.5 · 95% CI -1.1 to 0.0
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.2250 · Mean difference (final values): -0.4 · 95% CI -1.0 to 0.2
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.3728 · Mean difference (final values): -0.3 · 95% CI -0.9 to 0.3
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.2686 · Mean difference (final values): -0.3 · 95% CI -0.9 to 0.3
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0753 · Mean difference (final values): -0.6 · 95% CI -1.2 to 0.1
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1335 · Mean difference (final values): -0.5 · 95% CI -1.0 to 0.1
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0220 · Mean difference (final values): -0.7 · 95% CI -1.3 to -0.1
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.5754 · Mean difference (final values): -0.2 · 95% CI -0.8 to 0.4
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.3480 · Mean difference (final values): -0.3 · 95% CI -0.9 to 0.3
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0554 · Mean difference (final values): -0.6 · 95% CI -1.2 to 0.0
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.4362 · Mean difference (final values): -0.2 · 95% CI -0.8 to 0.4
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.3631 · Mean difference (final values): -0.3 · 95% CI -0.9 to 0.3
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1152 · Mean difference (final values): -0.5 · 95% CI -1.1 to 0.1
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.4741 · Mean difference (final values): -0.2 · 95% CI -0.8 to 0.4
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0091 · Mean difference (final values): -0.8 · 95% CI -1.4 to -0.2
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1721 · Mean difference (final values): -0.4 · 95% CI -1.0 to 0.2
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0262 · Mean difference (final values): -0.7 · 95% CI -1.3 to -0.1
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.9505 · Mean difference (final values): 0.0 · 95% CI -0.6 to 0.6
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.6877 · Mean difference (final values): -0.1 · 95% CI -0.7 to 0.5
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.1271 · Mean difference (final values): -0.5 · 95% CI -1.1 to 0.1
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.9136 · Mean difference (final values): -0.0 · 95% CI -0.6 to 0.6
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.4072 · Mean difference (final values): -0.3 · 95% CI -0.9 to 0.3
SecondarySubjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline

Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Total wake time after sleep onset subscale (in minutes): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Reduction = improvement. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Reported as:
Least squares mean · minutes
Subjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline
minutesPlaceboPregabalin 50 mg/DayPregabalin 100 mg/DayPregabalin 150 mg/DayPregabalin 300 mg/DayPregablin 450 mg/Day
Week 1-23.8 ± 7.44-37.9 ± 7.66-28.5 ± 7.47-29.0 ± 7.81-32.2 ± 7.58-32.6 ± 7.46
Week 2-29.5 ± 7.44-47.0 ± 7.79-36.5 ± 7.55-41.9 ± 8.23-39.8 ± 7.68-46.3 ± 7.57
Week 3-34.3 ± 7.62-51.4 ± 8.01-32.0 ± 7.47-45.9 ± 8.23-42.3 ± 7.59-42.9 ± 7.89
Week 4-30.4 ± 7.53-50.7 ± 8.01-36.5 ± 7.47-46.0 ± 8.23-43.6 ± 7.68-46.8 ± 7.79
Week 5-28.7 ± 7.62-55.4 ± 8.01-30.7 ± 7.47-59.6 ± 8.36-42.5 ± 7.59-55.1 ± 7.79
Week 6-34.2 ± 7.62-57.0 ± 7.90-34.2 ± 7.55-54.0 ± 8.49-41.1 ± 7.68-55.5 ± 7.89
Statistical analysis
  • Placebo vs Pregabalin 50 mg/Day · Mixed Models Analysis · p = 0.1860 · Mean difference (final values): -14.2 · 95% CI -35.2 to 6.9
  • Placebo vs Pregabalin 100 mg/Day · Mixed Models Analysis · p = 0.6530 · Mean difference (final values): -4.7 · 95% CI -25.5 to 16.0
  • Placebo vs Pregabalin 150 mg/Day · Mixed Models Analysis · p = 0.6263 · Mean difference (final values): -5.3 · 95% CI -26.5 to 16.0
  • Placebo vs Pregabalin 300 mg/Day · Mixed Models Analysis · p = 0.4266 · Mean difference (final values): -8.5 · 95% CI -29.4 to 12.5
  • Placebo vs Pregablin 450 mg/Day · Mixed Models Analysis · p = 0.4023 · Mean difference (final values): -8.8 · 95% CI -29.6 to 11.9
  • Placebo vs Pregabalin 50 mg/Day · Mixed Models Analysis · p = 0.1041 · Mean difference (final values): -17.6 · 95% CI -38.8 to 3.6
  • Placebo vs Pregabalin 100 mg/Day · Mixed Models Analysis · p = 0.5084 · Mean difference (final values): -7.0 · 95% CI -27.9 to 13.8
  • Placebo vs Pregabalin 150 mg/Day · Mixed Models Analysis · p = 0.2620 · Mean difference (final values): -12.5 · 95% CI -34.3 to 9.4
  • Placebo vs Pregabalin 300 mg/Day · Mixed Models Analysis · p = 0.3347 · Mean difference (final values): -10.3 · 95% CI -31.4 to 10.7
  • Placebo vs Pregablin 450 mg/Day · Mixed Models Analysis · p = 0.1142 · Mean difference (final values): -16.8 · 95% CI -37.7 to 4.1
  • Placebo vs Pregabalin 50 mg/Day · Mixed Models Analysis · p = 0.1237 · Mean difference (final values): -17.1 · 95% CI -38.8 to 4.7
  • Placebo vs Pregabalin 100 mg/Day · Mixed Models Analysis · p = 0.8302 · Mean difference (final values): 2.3 · 95% CI -18.7 to 23.3
  • Placebo vs Pregabalin 150 mg/Day · Mixed Models Analysis · p = 0.3039 · Mean difference (final values): -11.6 · 95% CI -33.6 to 10.5
  • Placebo vs Pregabalin 300 mg/Day · Mixed Models Analysis · p = 0.4595 · Mean difference (final values): -8.0 · 95% CI -29.2 to 13.2
  • Placebo vs Pregablin 450 mg/Day · Mixed Models Analysis · p = 0.4338 · Mean difference (final values): -8.6 · 95% CI -30.2 to 13.0
  • Placebo vs Pregabalin 50 mg/Day · Mixed Models Analysis · p = 0.0647 · Mean difference (final values): -20.4 · 95% CI -42.0 to 1.2
  • Placebo vs Pregabalin 100 mg/Day · Mixed Models Analysis · p = 0.5651 · Mean difference (final values): -6.1 · 95% CI -27.0 to 14.8
  • Placebo vs Pregabalin 150 mg/Day · Mixed Models Analysis · p = 0.1634 · Mean difference (final values): -15.6 · 95% CI -37.6 to 6.4
  • Placebo vs Pregabalin 300 mg/Day · Mixed Models Analysis · p = 0.2209 · Mean difference (final values): -13.2 · 95% CI -34.4 to 8.0
  • Placebo vs Pregablin 450 mg/Day · Mixed Models Analysis · p = 0.1293 · Mean difference (final values): -16.5 · 95% CI -37.8 to 4.8
  • Placebo vs Pregabalin 50 mg/Day · Mixed Models Analysis · p = 0.0161 · Mean difference (final values): -26.8 · 95% CI -48.5 to -5.0
  • Placebo vs Pregabalin 100 mg/Day · Mixed Models Analysis · p = 0.8506 · Mean difference (final values): -2.0 · 95% CI -23.0 to 19.0
  • Placebo vs Pregabalin 150 mg/Day · Mixed Models Analysis · p = 0.0067 · Mean difference (final values): -30.9 · 95% CI -53.2 to -8.6
  • Placebo vs Pregabalin 300 mg/Day · Mixed Models Analysis · p = 0.1997 · Mean difference (final values): -13.8 · 95% CI -35.0 to 7.4
  • Placebo vs Pregablin 450 mg/Day · Mixed Models Analysis · p = 0.0159 · Mean difference (final values): -26.4 · 95% CI -47.9 to -5.0
  • Placebo vs Pregabalin 50 mg/Day · Mixed Models Analysis · p = 0.0388 · Mean difference (final values): -22.8 · 95% CI -44.4 to -1.2
  • Placebo vs Pregabalin 100 mg/Day · Mixed Models Analysis · p = 0.9962 · Mean difference (final values): -0.1 · 95% CI -21.2 to 21.1
  • Placebo vs Pregabalin 150 mg/Day · Mixed Models Analysis · p = 0.0839 · Mean difference (final values): -19.8 · 95% CI -42.3 to 2.7
  • Placebo vs Pregabalin 300 mg/Day · Mixed Models Analysis · p = 0.5216 · Mean difference (final values): -6.9 · 95% CI -28.3 to 14.4
  • Placebo vs Pregablin 450 mg/Day · Mixed Models Analysis · p = 0.0534 · Mean difference (final values): -21.3 · 95% CI -42.9 to 0.3
SecondarySubjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline

Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Quality of sleep subscale: visual analog scale ranging from 1 (very poor) to 100 (excellent) completed by the subject 30 minutes after waking; recall period is the night before. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Reported as:
Least squares mean · scores on scale
Subjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 15.0 ± 4.1018.8 ± 4.2115.2 ± 4.1015.9 ± 4.2311.5 ± 4.1617.2 ± 4.11
Week 211.3 ± 4.1023.3 ± 4.2718.7 ± 4.1324.2 ± 4.4023.4 ± 4.2024.0 ± 4.16
Week 313.8 ± 4.1723.0 ± 4.3118.6 ± 4.1026.8 ± 4.4023.6 ± 4.2025.4 ± 4.29
Week 413.2 ± 4.1423.8 ± 4.3122.0 ± 4.1028.2 ± 4.4024.2 ± 4.2023.8 ± 4.25
Week 514.7 ± 4.1728.7 ± 4.3119.9 ± 4.1030.9 ± 4.4526.0 ± 4.2031.1 ± 4.25
Week 613.9 ± 4.1727.6 ± 4.3123.5 ± 4.1430.5 ± 4.5023.1 ± 4.2028.8 ± 4.25
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0199 · Mean difference (final values): 13.8 · 95% CI 2.2 to 25.4
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.0768 · Mean difference (final values): 10.3 · 95% CI -1.1 to 21.7
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0642 · Mean difference (final values): 11.0 · 95% CI -0.7 to 22.6
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.2643 · Median difference (final values): 6.6 · 95% CI -5.0 to 18.2
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0358 · Mean difference (final values): 12.2 · 95% CI 0.8 to 23.7
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0428 · Mean difference (final values): 12.1 · 95% CI 0.4 to 23.8
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.1993 · Mean difference (final values): 7.5 · 95% CI -4.0 to 18.9
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0331 · Mean difference (final values): 12.9 · 95% CI 1.1 to 24.8
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.0415 · Mean difference (final values): 12.1 · 95% CI 0.5 to 23.8
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0295 · Mean difference (final values): 12.8 · 95% CI 1.3 to 24.3
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1267 · Mean difference (final values): 9.2 · 95% CI -2.6 to 21.1
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.4175 · Mean difference (final values): 4.7 · 95% CI -6.8 to 16.2
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0342 · Mean difference (final values): 13.0 · 95% CI 1.0 to 25.0
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1038 · Mean difference (final values): 9.7 · 95% CI -2.0 to 21.5
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0537 · Mean difference (final values): 11.6 · 95% CI -0.2 to 23.4
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0772 · Mean difference (final values): 10.6 · 95% CI -1.2 to 22.4
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.1296 · Mean difference (final values): 8.8 · 95% CI -2.6 to 20.3
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0140 · Mean difference (final values): 15.0 · 95% CI 3.1 to 27.0
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.0642 · Mean difference (final values): 11.0 · 95% CI -0.7 to 22.7
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0730 · Mean difference (final values): 10.7 · 95% CI -1.0 to 22.3
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0215 · Mean difference (final values): 13.9 · 95% CI 2.1 to 25.8
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.3785 · Mean difference (final values): 5.2 · 95% CI -6.4 to 16.7
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0089 · Mean difference (final values): 16.1 · 95% CI 4.1 to 28.2
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.0609 · Mean difference (final values): 11.2 · 95% CI -0.5 to 23.0
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0064 · Mean difference (final values): 16.4 · 95% CI 4.7 to 28.1
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0241 · Mean difference (final values): 13.7 · 95% CI 1.8 to 25.5
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.1032 · Mean difference (final values): 9.6 · 95% CI -2.0 to 21.1
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0076 · Mean difference (final values): 16.6 · 95% CI 4.4 to 28.7
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1257 · Mean difference (final values): 9.2 · 95% CI -2.6 to 20.9
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0131 · Mean difference (final values): 14.9 · 95% CI 3.2 to 26.6
SecondaryMedical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline

MOS-SS: subject-rated instrument used to assess the key constructs of sleep quantity and quality over the past week; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Disturbance Subscale score (4 items): range 0-100; lower score indicates less disturbance. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6
Reported as:
Least squares mean · scores on scale
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 1-9.0 ± 4.76-18.2 ± 5.05-21.1 ± 4.87-23.0 ± 5.26-17.7 ± 4.93-26.3 ± 4.89
Week 2-15.7 ± 4.76-25.1 ± 5.14-23.0 ± 4.81-26.1 ± 5.30-35.3 ± 4.95-32.1 ± 5.02
Week 4-22.0 ± 4.81-18.5 ± 5.07-28.3 ± 4.76-32.4 ± 5.30-34.2 ± 4.95-37.4 ± 5.02
Week 6-19.3 ± 4.87-29.2 ± 5.14-25.3 ± 4.81-33.4 ± 5.38-31.4 ± 4.95-40.2 ± 5.02
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1824 · Mean difference (final values): -9.3 · 95% CI -23.0 to 4.4
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.0767 · Mean difference (final values): -12.1 · 95% CI -25.5 to 1.3
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0492 · Mean difference (final values): -14.1 · 95% CI -28.1 to -0.1
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.2023 · Mean difference (final values): -8.7 · 95% CI -22.2 to 4.7
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0116 · Mean difference (final values): -17.4 · 95% CI -30.9 to -3.9
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1819 · Mean difference (final values): -9.4 · 95% CI -23.2 to 4.4
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.2806 · Mean difference (final values): -7.3 · 95% CI -20.6 to 6.0
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.1465 · Mean difference (final values): -10.4 · 95% CI -24.4 to 3.7
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.0046 · Mean difference (final values): -19.6 · 95% CI -33.1 to -6.1
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0187 · Mean difference (final values): -16.4 · 95% CI -30.0 to -2.8
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.6128 · Mean difference (final values): 3.5 · 95% CI -10.2 to 17.3
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.3488 · Mean difference (final values): -6.4 · 95% CI -19.7 to 7.0
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.1472 · Mean difference (final values): -10.4 · 95% CI -24.5 to 3.7
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.0791 · Mean difference (final values): -12.2 · 95% CI -25.7 to 1.4
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0282 · Mean difference (final values): -15.4 · 95% CI -29.1 to -1.7
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1623 · Mean difference (final values): -9.9 · 95% CI -23.9 to 4.0
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.3739 · Mean difference (final values): -6.1 · 95% CI -19.6 to 7.4
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0517 · Mean difference (final values): -14.2 · 95% CI -28.5 to 0.1
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.0815 · Mean difference (final values): -12.1 · 95% CI -25.8 to 1.5
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0031 · Mean difference (final values): -20.9 · 95% CI -34.7 to -7.1
SecondaryMedical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline

MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality over the past week. Comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Snoring Subscale score (1 item): range 0-100, lower score indicates less snoring. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6
Reported as:
Least squares mean · scores on scale
Medical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 1-2.4 ± 5.395.2 ± 5.72-8.6 ± 5.530.7 ± 6.04-2.9 ± 5.46-9.2 ± 5.54
Week 2-1.5 ± 5.39-0.8 ± 5.81-11.4 ± 5.47-8.7 ± 6.16-3.3 ± 5.48-12.2 ± 5.66
Week 4-3.2 ± 5.444.4 ± 5.75-4.0 ± 5.42-7.5 ± 6.162.8 ± 5.48-3.5 ± 5.67
Week 6-2.1 ± 5.502.5 ± 5.81-6.6 ± 5.47-2.0 ± 6.241.0 ± 5.48-7.5 ± 5.67
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.3368 · Mean difference (final values): 7.6 · 95% CI -8.0 to 23.1
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.4232 · Mean difference (final values): -6.2 · 95% CI -21.5 to 9.1
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.7082 · Mean difference (final values): 3.0 · 95% CI -12.9 to 19.0
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.9466 · Mean difference (final values): -0.5 · 95% CI -15.7 to 14.7
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.3746 · Mean difference (final values): -6.9 · 95% CI -22.1 to 8.4
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.9336 · Mean difference (final values): 0.7 · 95% CI -15.0 to 16.3
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.2029 · Mean difference (final values): -9.8 · 95% CI -25.0 to 5.4
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.3833 · Mean difference (final values): -7.1 · 95% CI -23.3 to 9.0
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.8152 · Mean difference (final values): -1.8 · 95% CI -17.0 to 13.4
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.1739 · Mean difference (final values): -10.7 · 95% CI -26.1 to 4.7
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.3392 · Mean difference (final values): 7.6 · 95% CI -8.0 to 23.3
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.9130 · Mean difference (final values): -0.8 · 95% CI -16.0 to 14.4
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.6000 · Mean difference (final values): -4.3 · 95% CI -20.5 to 11.9
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.4445 · Mean difference (final values): 5.9 · 95% CI -9.3 to 21.2
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.9656 · Mean difference (final values): -0.3 · 95% CI -15.8 to 15.1
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.5679 · Mean difference (final values): 4.6 · 95% CI -11.2 to 20.4
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.5619 · Mean difference (final values): -4.5 · 95% CI -19.9 to 10.8
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.9930 · Mean difference (final values): 0.1 · 95% CI -16.3 to 16.4
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.6892 · Mean difference (final values): 3.1 · 95% CI -12.2 to 18.5
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.4928 · Mean difference (final values): -5.4 · 95% CI -21.0 to 10.1
SecondaryMedical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline

MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week ; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Awaken Short of Breath or with Headache subscale score range: 0-100; lower score indicates less difficulty. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6
Reported as:
Least squares mean · scores on scale
Medical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 1-7.3 ± 3.49-1.7 ± 3.72-5.3 ± 3.62-9.2 ± 3.92-8.6 ± 3.511.4 ± 3.58
Week 2-9.1 ± 3.49-4.3 ± 3.81-8.8 ± 3.54-12.1 ± 3.93-8.2 ± 3.53-1.1 ± 3.72
Week 4-9.9 ± 3.56-2.5 ± 3.73-8.9 ± 3.47-9.9 ± 3.93-9.1 ± 3.53-9.2 ± 3.73
Week 6-7.4 ± 3.63-0.9 ± 3.81-4.9 ± 3.54-11.5 ± 4.03-3.0 ± 3.53-8.2 ± 3.73
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.2719 · Mean difference (final values): 5.6 · 95% CI -4.4 to 15.6
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.6930 · Mean difference (final values): 2.0 · 95% CI -7.9 to 11.8
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.7178 · Mean difference (final values): -1.9 · 95% CI -12.2 to 8.4
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.8037 · Mean difference (final values): -1.2 · 95% CI -11.0 to 8.5
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0832 · Mean difference (final values): 8.7 · 95% CI -1.2 to 18.6
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.3554 · Mean difference (final values): 4.8 · 95% CI -5.4 to 14.9
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.9538 · Mean difference (final values): 0.3 · 95% CI -9.5 to 10.0
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.5593 · Mean difference (final values): -3.1 · 95% CI -13.4 to 7.3
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.8663 · Mean difference (final values): 0.8 · 95% CI -8.9 to 10.6
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.1190 · Mean difference (final values): 8.0 · 95% CI -2.1 to 18.1
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1544 · Mean difference (final values): 7.4 · 95% CI -2.8 to 17.5
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.8439 · Mean difference (final values): 1.0 · 95% CI -8.8 to 10.7
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.9925 · Mean difference (final values): -0.0 · 95% CI -10.5 to 10.4
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.8784 · Mean difference (final values): 0.8 · 95% CI -9.1 to 10.6
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.8948 · Mean difference (final values): 0.7 · 95% CI -9.5 to 10.8
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.2197 · Mean difference (final values): 6.5 · 95% CI -3.9 to 16.8
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.6183 · Mean difference (final values): 2.5 · 95% CI -7.4 to 12.5
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.4484 · Mean difference (final values): -4.1 · 95% CI -14.8 to 6.5
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.3857 · Mean difference (final values): 4.4 · 95% CI -5.6 to 14.4
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.8824 · Mean difference (final values): -0.8 · 95% CI -11.0 to 9.5
SecondaryMedical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline

MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Adequacy Subscale score range: 0-100; higher scores indicates greater sleep adequacy. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6
Reported as:
Least squares mean · scores on scale
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 15.2 ± 5.3816.1 ± 5.765.3 ± 5.5313.7 ± 6.019.8 ± 5.5016.1 ± 5.58
Week 215.6 ± 5.3831.0 ± 5.8719.6 ± 5.4521.9 ± 6.0614.0 ± 5.5329.5 ± 5.76
Week 415.6 ± 5.4523.9 ± 5.7820.8 ± 5.3824.7 ± 6.0626.6 ± 5.5334.6 ± 5.78
Week 616.8 ± 5.5434.6 ± 5.8727.0 ± 5.4526.8 ± 6.1719.2 ± 5.5331.1 ± 5.78
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1673 · Mean difference (final values): 10.9 · 95% CI -4.6 to 26.4
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.9839 · Mean difference (final values): 0.2 · 95% CI -15.0 to 15.3
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.2905 · Mean difference (final values): 8.5 · 95% CI -7.3 to 24.4
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.5513 · Mean difference (final values): 4.6 · 95% CI -10.6 to 19.7
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.1589 · Mean difference (final values): 11.0 · 95% CI -4.3 to 26.3
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0541 · Mean difference (final values): 15.4 · 95% CI -0.3 to 31.0
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.5987 · Mean difference (final values): 4.0 · 95% CI -11.0 to 19.1
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.4372 · Mean difference (final values): 6.3 · 95% CI -9.6 to 22.2
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.8336 · Mean difference (final values): -1.6 · 95% CI -16.8 to 13.6
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0804 · Mean difference (final values): 13.9 · 95% CI -1.7 to 29.4
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.2985 · Mean difference (final values): 8.3 · 95% CI -7.4 to 23.9
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.4991 · Mean difference (final values): 5.2 · 95% CI -9.9 to 20.3
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.2675 · Mean difference (final values): 9.1 · 95% CI -7.0 to 25.1
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1593 · Mean difference (final values): 11.0 · 95% CI -4.3 to 26.3
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0179 · Mean difference (final values): 18.9 · 95% CI 3.3 to 34.6
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0281 · Mean difference (final values): 17.8 · 95% CI 1.9 to 33.7
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.1883 · Mean difference (final values): 10.3 · 95% CI -5.0 to 25.5
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.2300 · Mean difference (final values): 10.0 · 95% CI -6.3 to 26.3
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.7575 · Mean difference (final values): 2.4 · 95% CI -13.0 to 17.8
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0757 · Mean difference (final values): 14.3 · 95% CI -1.5 to 30.1
SecondaryMedical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline

MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Somnolence Subscale score range: 0-100; higher score indicates less somnolence. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline,, Week 1, Week 2, Week 4, Week 6
Reported as:
Least squares mean · scores on scale
Medical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 1-7.4 ± 4.02-13.8 ± 4.29-9.8 ± 4.12-14.3 ± 4.46-11.2 ± 4.07-10.7 ± 4.14
Week 2-13.9 ± 4.02-18.2 ± 4.36-11.1 ± 4.07-18.8 ± 4.49-11.3 ± 4.09-12.6 ± 4.25
Week 4-14.0 ± 4.07-20.4 ± 4.30-11.8 ± 4.02-16.2 ± 4.49-16.9 ± 4.09-12.6 ± 4.26
Week 6-11.7 ± 4.12-26.3 ± 4.36-14.8 ± 4.07-21.7 ± 4.56-13.4 ± 4.09-13.9 ± 4.26
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.2817 · Mean difference (final values): -6.4 · 95% CI -18.0 to 5.2
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.6796 · Mean difference (final values): -2.4 · 95% CI -13.7 to 9.0
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.2505 · Mean difference (final values): -6.9 · 95% CI -18.8 to 4.9
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.5102 · Mean difference (final values): -3.8 · 95% CI -15.1 to 7.5
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.5706 · Mean difference (final values): -3.3 · 95% CI -14.7 to 8.1
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.4708 · Mean difference (final values): -4.3 · 95% CI -16.0 to 7.4
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.6202 · Mean difference (final values): 2.8 · 95% CI -8.4 to 14.1
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.4177 · Mean difference (final values): -4.9 · 95% CI -16.8 to 7.0
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.6509 · Mean difference (final values): 2.6 · 95% CI -8.7 to 13.9
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.8273 · Mean difference (final values): 1.3 · 95% CI -10.3 to 12.8
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.2842 · Mean difference (final values): -6.4 · 95% CI -18.1 to 5.3
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.7041 · Mean difference (final values): 2.2 · 95% CI -9.1 to 13.5
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.7216 · Mean difference (final values): -2.2 · 95% CI -14.1 to 9.8
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.6188 · Mean difference (final values): -2.9 · 95% CI -14.3 to 8.5
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.8096 · Mean difference (final values): 1.4 · 95% CI -10.2 to 13.0
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0157 · Mean difference (final values): -14.6 · 95% CI -26.5 to -2.8
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.6007 · Mean difference (final values): -3.0 · 95% CI -14.4 to 8.4
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.1057 · Mean difference (final values): -10.0 · 95% CI -22.1 to 2.1
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.7764 · Mean difference (final values): -1.7 · 95% CI -13.1 to 9.8
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.7146 · Mean difference (final values): -2.2 · 95% CI -13.9 to 9.5
SecondaryMedical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline

MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Quantity (1 item) subscale score range: 0-24 hours. Change from Baseline in number of hours slept. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline,, Week 1, Week 2, Week 4, Week 6
Reported as:
Least squares mean · scores on scale
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 10.4 ± 0.210.7 ± 0.220.5 ± 0.220.9 ± 0.230.4 ± 0.210.7 ± 0.22
Week 20.5 ± 0.210.8 ± 0.230.6 ± 0.211.2 ± 0.230.7 ± 0.211.1 ± 0.22
Week 40.6 ± 0.211.0 ± 0.220.7 ± 0.211.4 ± 0.231.1 ± 0.211.1 ± 0.22
Week 60.6 ± 0.220.9 ± 0.230.7 ± 0.211.3 ± 0.240.7 ± 0.211.2 ± 0.22
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.2978 · Mean difference (final values): 0.3 · 95% CI -0.3 to 0.9
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.7242 · Mean difference (final values): 0.1 · 95% CI -0.5 to 0.7
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0773 · Mean difference (final values): 0.6 · 95% CI -0.1 to 1.2
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.7831 · Mean difference (final values): 0.1 · 95% CI -0.5 to 0.7
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.3291 · Mean difference (final values): 0.3 · 95% CI -0.3 to 0.9
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.3692 · Mean difference (final values): 0.3 · 95% CI -0.3 to 0.9
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.7614 · Mean difference (final values): 0.1 · 95% CI -0.5 to 0.7
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0355 · Mean difference (final values): 0.7 · 95% CI 0.0 to 1.3
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.5068 · Mean difference (final values): 0.2 · 95% CI -0.4 to 0.8
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0561 · Mean difference (final values): 0.6 · 95% CI -0.0 to 1.2
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.2223 · Mean difference (final values): 0.4 · 95% CI -0.2 to 1.0
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.6791 · Mean difference (final values): 0.1 · 95% CI -0.5 to 0.7
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0188 · Mean difference (final values): 0.8 · 95% CI 0.1 to 1.4
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1314 · Mean difference (final values): 0.5 · 95% CI -0.1 to 1.1
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0900 · Mean difference (final values): 0.5 · 95% CI -0.1 to 1.1
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.4144 · Mean difference (final values): 0.3 · 95% CI -0.4 to 0.9
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.7699 · Mean difference (final values): 0.1 · 95% CI -0.5 to 0.7
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0406 · Mean difference (final values): 0.7 · 95% CI 0.0 to 1.3
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.7574 · Mean difference (final values): 0.1 · 95% CI -0.5 to 0.7
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0554 · Mean difference (final values): 0.6 · 95% CI -0.0 to 1.2
SecondaryMedical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline

MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Problems Index I (6 items): composite index score range 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6
Reported as:
Least squares mean · scores on scale
Medical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 1-9.2 ± 3.67-12.5 ± 3.91-10.4 ± 3.75-14.9 ± 4.06-13.9 ± 3.77-16.2 ± 3.77
Week 2-14.8 ± 3.67-22.0 ± 3.97-15.7 ± 3.71-20.3 ± 4.09-20.1 ± 3.79-24.1 ± 3.87
Week 4-17.2 ± 3.71-17.9 ± 3.92-19.6 ± 3.67-23.3 ± 4.09-24.4 ± 3.79-28.9 ± 3.88
Week 6-15.5 ± 3.76-25.0 ± 3.97-21.1 ± 3.71-26.1 ± 4.15-18.8 ± 3.79-27.6 ± 3.88
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.5409 · Mean difference (final values): -3.3 · 95% CI -13.8 to 7.3
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.8230 · Mean difference (final values): -1.2 · 95% CI -11.5 to 9.2
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.2958 · Mean difference (final values): -5.7 · 95% CI -16.5 to 5.1
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.3708 · Mean difference (final values): -4.7 · 95% CI -15.1 to 5.7
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.1853 · Mean difference (final values): -7.0 · 95% CI -17.4 to 3.4
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1834 · Mean difference (final values): -7.2 · 95% CI -17.9 to 3.4
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.8711 · Mean difference (final values): -0.8 · 95% CI -11.1 to 9.4
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.3252 · Mean difference (final values): -5.4 · 95% CI -16.3 to 5.4
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.3205 · Mean difference (final values): -5.3 · 95% CI -15.7 to 5.1
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0837 · Mean difference (final values): -9.3 · 95% CI -19.8 to 1.2
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.8895 · Mean difference (final values): -0.8 · 95% CI -11.4 to 9.9
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.6469 · Mean difference (final values): -2.4 · 95% CI -12.7 to 7.9
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.2687 · Mean difference (final values): -6.1 · 95% CI -17.0 to 4.8
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1757 · Mean difference (final values): -7.2 · 95% CI -17.7 to 3.3
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0306 · Mean difference (final values): -11.7 · 95% CI -22.3 to -1.1
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0857 · Mean difference (final values): -9.4 · 95% CI -20.2 to 1.3
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.2932 · Mean difference (final values): -5.6 · 95% CI -16.0 to 4.8
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0613 · Mean difference (final values): -10.5 · 95% CI -21.6 to 0.5
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.5431 · Mean difference (final values): -3.3 · 95% CI -13.8 to 7.3
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0262 · Mean difference (final values): -12.1 · 95% CI -22.7 to -1.4
SecondaryMedical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline

MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Composite index scores are sleep problems Index I (6 items) and sleep problems Index II (9 items). 9-Item Sleep Problems Index range: 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6
Reported as:
Least squares mean · scores on scale
Medical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 1-8.1 ± 3.73-15.9 ± 3.96-14.2 ± 3.81-17.8 ± 4.12-14.4 ± 3.84-18.8 ± 3.83
Week 2-15.5 ± 3.73-23.5 ± 4.03-19.0 ± 3.76-22.5 ± 4.15-23.3 ± 3.86-24.6 ± 3.93
Week 4-18.2 ± 3.77-19.3 ± 3.98-22.0 ± 3.73-25.2 ± 4.15-27.0 ± 3.86-29.1 ± 3.93
Week 6-16.8 ± 3.81-27.5 ± 4.03-22.2 ± 3.76-28.3 ± 4.21-22.3 ± 3.86-29.4 ± 3.93
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1547 · Mean difference (final values): -7.8 · 95% CI -18.5 to 3.0
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.2532 · Mean difference (final values): -6.1 · 95% CI -16.6 to 4.4
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0848 · Mean difference (final values): -9.6 · 95% CI -20.6 to 1.3
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.2424 · Mean difference (final values): -6.3 · 95% CI -16.8 to 4.3
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0470 · Mean difference (final values): -10.7 · 95% CI -21.2 to -0.1
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.1494 · Mean difference (final values): -7.9 · 95% CI -18.8 to 2.9
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.5081 · Mean difference (final values): -3.5 · 95% CI -13.9 to 6.9
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.2141 · Mean difference (final values): -7.0 · 95% CI -17.9 to 4.0
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1484 · Mean difference (final values): -7.8 · 95% CI -18.4 to 2.8
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0963 · Mean difference (final values): -9.0 · 95% CI -19.7 to 1.6
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.8519 · Mean difference (final values): -1.0 · 95% CI -11.8 to 9.8
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.4770 · Mean difference (final values): -3.8 · 95% CI -14.2 to 6.7
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.2166 · Mean difference (final values): -6.9 · 95% CI -18.0 to 4.1
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.1062 · Mean difference (final values): -8.8 · 95% CI -19.4 to 1.9
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0475 · Mean difference (final values): -10.9 · 95% CI -21.6 to -0.1
  • Placebo vs Pregabalin 50 mg · Mixed Models Analysis · p = 0.0537 · Mean difference (final values): -10.7 · 95% CI -21.7 to 0.2
  • Placebo vs Pregabalin 100 mg · Mixed Models Analysis · p = 0.3153 · Mean difference (final values): -5.4 · 95% CI -15.9 to 5.2
  • Placebo vs Pregabalin 150 mg · Mixed Models Analysis · p = 0.0424 · Mean difference (final values): -11.6 · 95% CI -22.8 to -0.4
  • Placebo vs Pregabalin 300 mg · Mixed Models Analysis · p = 0.3077 · Mean difference (final values): -5.5 · 95% CI -16.2 to 5.1
  • Placebo vs Pregabalin 450 mg · Mixed Models Analysis · p = 0.0224 · Mean difference (final values): -12.6 · 95% CI -23.4 to -1.8
SecondaryMedical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week

MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Optimal Sleep subscale is derived from sleep quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours of sleep per night.

Time frame:
Week 1, Week 2, Week 4, Week 6
Reported as:
Number · participants
Medical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week
participantsPlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Week 161079611
Week 2861191212
Week 4111211101411
Week 612111110913
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Regression, Logistic · p = 0.0646 · Odds ratio (or): 3.7 · 95% CI 0.9 to 15.0
  • Placebo vs Pregabalin 100 mg · Regression, Logistic · p = 0.2947 · Odds ratio (or): 2.2 · 95% CI 0.5 to 9.1
  • Placebo vs Pregabalin 150 mg · Regression, Logistic · p = 0.0249 · Odds ratio (or): 4.6 · 95% CI 1.2 to 17.2
  • Placebo vs Pregabalin 300 mg · Regression, Logistic · p = 0.7671 · Odds ratio (or): 1.3 · 95% CI 0.3 to 5.9
  • Placebo vs Pregabalin 450 mg · Regression, Logistic · p = 0.0169 · Odds ratio (or): 4.6 · 95% CI 1.3 to 15.9
  • Placebo vs Pregabalin 50 mg · Regression, Logistic · p = 0.9569 · Odds ratio (or): 1.0 · 95% CI 0.2 to 4.3
  • Placebo vs Pregabalin 100 mg · Regression, Logistic · p = 0.0711 · Odds ratio (or): 3.2 · 95% CI 0.9 to 11.4
  • Placebo vs Pregabalin 150 mg · Regression, Logistic · p = 0.1073 · Odds ratio (or): 2.8 · 95% CI 0.8 to 10.2
  • Placebo vs Pregabalin 300 mg · Regression, Logistic · p = 0.1583 · Odds ratio (or): 2.4 · 95% CI 0.7 to 8.1
  • Placebo vs Pregabalin 450 mg · Regression, Logistic · p = 0.0385 · Odds ratio (or): 4.1 · 95% CI 1.1 to 15.6
  • Placebo vs Pregabalin 50 mg · Regression, Logistic · p = 0.4923 · Odds ratio (or): 1.6 · 95% CI 0.4 to 6.1
  • Placebo vs Pregabalin 100 mg · Regression, Logistic · p = 0.7169 · Odds ratio (or): 1.3 · 95% CI 0.4 to 4.4
  • Placebo vs Pregabalin 150 mg · Regression, Logistic · p = 0.4156 · Odds ratio (or): 1.7 · 95% CI 0.5 to 6.2
  • Placebo vs Pregabalin 300 mg · Regression, Logistic · p = 0.4165 · Odds ratio (or): 1.7 · 95% CI 0.5 to 5.6
  • Placebo vs Pregabalin 450 mg · Regression, Logistic · p = 0.4673 · Odds ratio (or): 1.6 · 95% CI 0.4 to 6.0
  • Placebo vs Pregabalin 50 mg · Regression, Logistic · p = 0.9855 · Odds ratio (or): 1.0 · 95% CI 0.2 to 4.1
  • Placebo vs Pregabalin 100 mg · Regression, Logistic · p = 0.9566 · Odds ratio (or): 1.0 · 95% CI 0.3 to 3.3
  • Placebo vs Pregabalin 150 mg · Regression, Logistic · p = 0.4632 · Odds ratio (or): 1.7 · 95% CI 0.4 to 6.6
  • Placebo vs Pregabalin 300 mg · Regression, Logistic · p = 0.2042 · Odds ratio (or): 0.4 · 95% CI 0.1 to 1.6
  • Placebo vs Pregabalin 450 mg · Regression, Logistic · p = 0.3382 · Odds ratio (or): 1.9 · 95% CI 0.5 to 7.5
SecondaryRestless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6

RLS QoL: subject-rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life. Recall period is the month prior to the assessment. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · scores on scales
Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6
scores on scalesPlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 615.0 ± 3.7119.6 ± 3.8722.4 ± 3.5520.8 ± 3.9415.9 ± 3.6320.5 ± 3.74
Statistical analysis
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.3932 · Mean difference (final values): 4.6 · 95% CI -6.0 to 15.2
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.1585 · Mean difference (final values): 7.3 · 95% CI -2.9 to 17.5
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.2850 · Mean difference (final values): 5.8 · 95% CI -4.9 to 16.5
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.8645 · Mean difference (final values): 0.9 · 95% CI -9.4 to 11.1
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.3031 · Mean difference (final values): 5.4 · 95% CI -5.0 to 15.8
SecondaryMedical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Recall period: month prior to the assessment. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · scores on scale
Medical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6
scores on scalePlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Physical Functioning3.6 ± 3.500.5 ± 3.712.4 ± 3.42-0.4 ± 3.932.9 ± 3.523.6 ± 3.62
Role-Physical1.1 ± 4.247.0 ± 4.497.5 ± 4.147.7 ± 4.770.9 ± 4.249.6 ± 4.40
Bodily Pain6.9 ± 4.1615.8 ± 4.4112.9 ± 4.0716.9 ± 4.8713.3 ± 4.1718.1 ± 4.31
General Health6.5 ± 2.815.2 ± 3.054.0 ± 2.757.5 ± 3.153.6 ± 2.825.9 ± 2.90
Vitality7.4 ± 3.9811.1 ± 4.189.9 ± 3.8618.5 ± 4.4611.7 ± 3.9513.9 ± 4.08
Social Functioning7.8 ± 3.988.3 ± 4.204.8 ± 3.884.4 ± 4.479.5 ± 4.0015.6 ± 4.10
Role-Emotional-2.1 ± 4.166.7 ± 4.387.8 ± 4.051.0 ± 4.638.1 ± 4.1312.7 ± 4.31
Mental Health2.9 ± 3.491.0 ± 3.683.6 ± 3.437.6 ± 3.903.7 ± 3.4710.7 ± 3.59
Summary Physical Score4.5 ± 2.837.4 ± 3.026.7 ± 2.778.2 ± 3.295.6 ± 2.859.7 ± 2.94
Summary Emotional Score3.7 ± 3.336.9 ± 3.516.7 ± 3.248.2 ± 3.728.5 ± 3.3213.5 ± 3.43
Statistical analysis
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.5384 · Mean difference (final values): -3.1 · 95% CI -13.2 to 7.0
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.8015 · Mean difference (final values): -1.2 · 95% CI -10.9 to 8.5
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.4429 · Mean difference (final values): -4.1 · 95% CI -14.5 to 6.4
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.8860 · Mean difference (final values): -0.7 · 95% CI -10.5 to 9.1
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.9963 · Mean difference (final values): -0.0 · 95% CI -10.0 to 9.9
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.3421 · Mean difference (final values): 5.9 · 95% CI -6.3 to 18.1
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.2849 · Mean difference (final values): 6.4 · 95% CI -5.4 to 18.1
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.3058 · Mean difference (final values): 6.6 · 95% CI -6.1 to 19.2
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.9604 · Mean difference (final values): -0.3 · 95% CI -12.1 to 11.5
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.1661 · Mean difference (final values): 8.5 · 95% CI -3.6 to 20.6
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.1441 · Mean difference (final values): 8.9 · 95% CI -3.1 to 20.9
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.3076 · Mean difference (final values): 6.0 · 95% CI -5.6 to 17.5
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.1209 · Mean difference (final values): 10.0 · 95% CI -2.7 to 22.7
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.2791 · Mean difference (final values): 6.4 · 95% CI -5.3 to 18.0
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.0644 · Mean difference (final values): 11.2 · 95% CI -0.7 to 23.0
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.7544 · Mean difference (final values): -1.3 · 95% CI -9.5 to 6.9
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.5142 · Mean difference (final values): -2.6 · 95% CI -10.3 to 5.2
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.8158 · Mean difference (final values): 1.0 · 95% CI -7.4 to 9.4
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.4599 · Mean difference (final values): -2.9 · 95% CI -10.8 to 4.9
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.8636 · Mean difference (final values): -0.7 · 95% CI -8.7 to 7.3
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.5281 · Mean difference (final values): 3.7 · 95% CI -7.8 to 15.1
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.6566 · Mean difference (final values): 2.5 · 95% CI -8.5 to 13.5
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.0677 · Mean difference (final values): 11.1 · 95% CI -0.8 to 23.0
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.4443 · Mean difference (final values): 4.3 · 95% CI -6.8 to 15.4
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.2543 · Mean difference (final values): 6.5 · 95% CI -4.7 to 17.7
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.9416 · Mean difference (final values): 0.4 · 95% CI -11.0 to 11.9
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.5824 · Mean difference (final values): -3.1 · 95% CI -14.1 to 7.9
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.5668 · Mean difference (final values): -3.4 · 95% CI -15.3 to 8.4
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.7769 · Mean difference (final values): 1.6 · 95% CI -9.6 to 12.8
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.1753 · Mean difference (final values): 7.8 · 95% CI -3.5 to 19.1
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.1508 · Mean difference (final values): 8.7 · 95% CI -3.2 to 20.7
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.0916 · Mean difference (final values): 9.9 · 95% CI -1.6 to 21.4
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.6222 · Mean difference (final values): 3.1 · 95% CI -9.2 to 15.4
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.0850 · Mean difference (final values): 10.2 · 95% CI -1.4 to 21.8
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.0154 · Mean difference (final values): 14.8 · 95% CI 2.9 to 26.7
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.7201 · Mean difference (final values): -1.8 · 95% CI -11.9 to 8.2
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.8875 · Mean difference (final values): 0.7 · 95% CI -9.1 to 10.5
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.3735 · Mean difference (final values): 4.7 · 95% CI -5.7 to 15.1
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.8621 · Mean difference (final values): 0.9 · 95% CI -8.9 to 10.6
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.1203 · Mean difference (final values): 7.9 · 95% CI -2.1 to 17.8
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.4966 · Mean difference (final values): 2.8 · 95% CI -5.4 to 11.0
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.5776 · Mean difference (final values): 2.2 · 95% CI -5.6 to 10.1
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.3955 · Mean difference (final values): 3.7 · 95% CI -4.9 to 12.3
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.7994 · Mean difference (final values): 1.0 · 95% CI -6.9 to 9.0
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.2073 · Mean difference (final values): 5.2 · 95% CI -2.9 to 13.2
  • Placebo vs Pregabalin 50 mg · ANCOVA · p = 0.5148 · Mean difference (final values): 3.2 · 95% CI -6.4 to 12.8
  • Placebo vs Pregabalin 100 mg · ANCOVA · p = 0.5255 · Mean difference (final values): 3.0 · 95% CI -6.3 to 12.2
  • Placebo vs Pregabalin 150 mg · ANCOVA · p = 0.3793 · Mean difference (final values): 4.4 · 95% CI -5.5 to 14.4
  • Placebo vs Pregabalin 300 mg · ANCOVA · p = 0.3120 · Mean difference (final values): 4.8 · 95% CI -4.5 to 14.1
  • Placebo vs Pregabalin 450 mg · ANCOVA · p = 0.0442 · Mean difference (final values): 9.7 · 95% CI 0.3 to 19.2
SecondaryMedical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Self-evaluated change in health status: 5 Likert-type response categories ranging from "much worse now" to much better now." Recall period: month prior to the assessment.

Time frame:
Baseline, Week 6
Reported as:
Number · participants
Medical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores
participantsPlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Baseline: Much Worse than 1 Year Ago031232
Baseline: Somewhat Worse than 1 Year Ago463413
Baseline: About the Same as 1 Year Ago15915141412
Baseline: Somewhat Better than 1 Year Ago213052
Baseline: Much Better than 1 Year Ago111012
Week 6: Much Worse than 1 Year Ago100020
Week 6: Somewhat Worse than 1 Year Ago232431
Week 6: About the Same as 1 Year Ago111210111210
Week 6: Somewhat Better than 1 Year Ago424145
Week 6: Much Better than 1 Year Ago326124
Statistical analysis
  • Placebo vs Pregabalin 50 mg · Cochran-Mantel-Haenszel · p = 0.4452
  • Placebo vs Pregabalin 100 mg · Cochran-Mantel-Haenszel · p = 0.4342
  • Placebo vs Pregabalin 150 mg · Cochran-Mantel-Haenszel · p = 0.0942
  • Placebo vs Pregabalin 300 mg · Cochran-Mantel-Haenszel · p = 0.1873
  • Placebo vs Pregabalin 450 mg · Cochran-Mantel-Haenszel · p = 0.4709

Adverse events

Non-serious events are listed at a 1.45% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/23 (0%)13/23 (56.5%)
Pregabalin 50 mg—1/22 (4.5%)9/22 (40.9%)
Pregabalin 100 mg—0/23 (0%)12/23 (52.2%)
Pregabalin 150 mg—0/22 (0%)15/22 (68.2%)
Pregabalin 300 mg—0/24 (0%)17/24 (70.8%)
Pregabalin 450 mg—0/23 (0%)19/23 (82.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/231/220/230/220/240/23
Most frequent other events
Showing 10 of 106
Most frequent other events
EventPlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mg
DizzinessNervous system disorders1/230/222/235/222/247/23
SomnolenceNervous system disorders1/230/221/236/226/245/23
HeadacheNervous system disorders3/235/222/232/224/242/23
FatigueGeneral disorders0/230/224/232/221/242/23
Abnormal dreamsPsychiatric disorders3/230/220/230/220/240/23
Dry mouthGastrointestinal disorders0/230/220/231/223/242/23
NauseaGastrointestinal disorders1/231/220/232/220/240/23
Hot flushVascular disorders1/230/220/232/221/240/23
Vision blurredEye disorders0/230/220/232/221/242/23
Feeling drunkGeneral disorders0/230/220/230/221/242/23

Baseline characteristics

Age, Customized
Age, Customized(participants)PlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mgTotal
18 - 44 years45729330
45 - 64 years191516201519104
>=65 years0200013
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPregabalin 50 mgPregabalin 100 mgPregabalin 150 mgPregabalin 300 mgPregabalin 450 mgTotal
Female13131613191690
Male109795747
08

Study locations

25 sites
  • Pfizer Investigational Site
    Tuscaloosa, Alabama 35406, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    San Diego, California 92121, United States
  • Pfizer Investigational Site
    Santa Monica, California 90404, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80012, United States
  • Pfizer Investigational Site
    Brandon, Florida 33511, United States
  • Pfizer Investigational Site
    Macon, Georgia 31201, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40217, United States
  • Pfizer Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27607, United States
  • Pfizer Investigational Site
    Salisbury, North Carolina 28144, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    Alexandria, Virginia 22311, United States
  • Pfizer Investigational Site
    Innsbruck, A-6020, Austria
  • Pfizer Investigational Site
    Vienna, A-1080, Austria
  • Pfizer Investigational Site
    Bad Saarow, 15526, Germany
  • Pfizer Investigational Site
    Berlin, 10969, Germany
  • Pfizer Investigational Site
    Goettingen, 37075, Germany
  • Pfizer Investigational Site
    Mittweida, 09648, Germany
  • Pfizer Investigational Site
    Muenchen, 80331, Germany
  • Pfizer Investigational Site
    Oldenburg, 26122, Germany
  • Pfizer Investigational Site
    Schwerin, 19053, Germany
  • Pfizer Investigational Site
    Madrid, 28036, Spain
09

References and documents

Publications

  • Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, Garcia-Borreguero D, Miceli J. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010 Jun;11(6):512-9. doi: 10.1016/j.sleep.2010.03.003. Epub 2010 May 13. PubMed 20466589 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2008
First posted
May 13, 2008
Start
Apr 2008
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Feb 4, 2010
Last update
Feb 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00676403
Responsible party
Sponsor
First posted
May 13, 2008
Start date
Apr 2008
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Feb 4, 2010
Last update
Feb 10, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion